Drug intelligence / Profile preview

ADSC-TM cells

Development stage: Preclinical
Modality: Stem Cell Therapies → Cell Therapies
Administration: Ophthalmic (intracameral Injection)

Overview

ADSC-TM cells are differentiated cells derived from **adipose-derived stem cells (ADSCs)**, which are induced to express characteristics of **trabecular meshwork (TM) cells**. These cells are used in research as a potential treatment for glaucoma by integrating into the TM tissue to restore its function and maintain intraocular pressure (IOP). They are capable of phagocytosis and respond to dexamethasone stimulation, displaying markers such as **CHI3L1** and **AQP1**.

Other names: Trabecular meshwork-like cells differentiated from adipose-derived stem cells

Beyond the preview

Go deeper on ADSC-TM cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADSC-TM cells.

Explore the full profile